Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Factor Xa/genetics"'
Autor:
Julien Favresse, Michael Hardy, Charles-Marc Samama, A L Sennesael, M A van Dievoet, Ovidiu Ionut Vornicu, Sarah Lessire, Anne-Sophie Dincq, François Mullier, Jonathan Douxfils
Publikováno v:
Expert opinion on biological therapy, Vol. 19, no. 5, p. 387-397 (2019)
INTRODUCTION: Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. Since May 2018, the FDA has approved its utilization in patients treated with apixaban and rivaroxaban in case of life-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73978cdb0cfdbfd5d9a6913386796243
https://pubmed.ncbi.nlm.nih.gov/30974977
https://pubmed.ncbi.nlm.nih.gov/30974977
Publikováno v:
Drug Week; 7/5/2024, p700-700, 1p
Patent Issued for Antidotes for factor Xa inhibitors and methods of using the same (USPTO 11839646).
Publikováno v:
Hematology Week; 1/5/2024, p710-710, 1p
Publikováno v:
Drug Week; 12/22/2023, p1156-1156, 1p